The FDA has approved the first gene therapy aimed at restoring hearing for individuals born deaf. This groundbreaking treatment was developed by Regeneron Pharmaceuticals.
Key points
FDA approved first gene therapy for deafness
Treatment restores hearing for individuals born deaf
Developed by Regeneron Pharmaceuticals
Mentioned in this story
Regeneron Pharmaceuticals
FDA
Sierra Smith holds her son, Travis, whose deafness was successfully treated with gene therapy.
Sierra Smith holds her son, Travis, whose deafness was successfully treated with gene therapy.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss.
"It's the first time in history there's a new drug for hearing loss," says Zheng-Yi Chen, an associate scientist at in Boston who was not involved in the development of the therapy approved by the FDA Thursday. But his research team very promising results with a similar approach Wednesday. "I think it's an historical event, a landmark, a great development for the whole field," he says of the approval.
Q&A
What is the first gene therapy approved for deafness?
The first gene therapy approved for deafness is a treatment developed by Regeneron Pharmaceuticals that aims to restore hearing for individuals born deaf.
How does the FDA's approval of gene therapy for deafness impact patients?
The FDA's approval provides a new treatment option for patients born deaf, potentially improving their quality of life by restoring hearing.
Who developed the gene therapy for deafness approved by the FDA?
The gene therapy for deafness approved by the FDA was developed by Regeneron Pharmaceuticals.
What are the implications of FDA approval for gene therapy in hearing restoration?
The FDA approval signifies a major advancement in medical science, paving the way for future gene therapies that could address other genetic conditions.
When Sierra Smith gave birth to her son, Travis, the hospital immediately told her something was wrong.
"The hospital told me that he failed his newborn hearing test. But they thought it was just fluid in the ears and that it would be fine in a couple of months," says Smith, 26, who lives in East Greenbush, N.Y.
But he wasn't. It turned out Travis was born with a rare genetic defect that had left him profoundly deaf.
"He was 100% deaf," Smith says. "Everything we do — slamming pots and pans together, yelling his name – there was nothing at all."
An experimental gene therapy offers hope
But then Smith heard about an experimental treatment that might help her son. Doctors would infuse a virus into her son's ears carrying a gene for a protein called otoferlin, which Travis was missing, hopefully restoring the ability of his brain to receive signals from his ears. She jumped at the chance to try it at Columbia University in New York.
"About two and a half to three months after, we were driving in the car and he was sleeping. And I laughed really loud, and he startled for the first time ever. He, like, jumped in his sleep," Smith says. "And I looked at my friend and I was, like: 'Oh my goodness. Like, did he hear that?' And so we started yelling and making loud noises and, like, sure enough, he started waking up."
Smith adds: "That was like the most surreal moment a mother can feel when your son first hears your voice."
"I'm absolutely thrilled," says Jonathon Whitton, vice president for genetic medicines, at Regeneron Pharmaceuticals, which developed the gene therapy and plans to offer it for free in the U.S. It should be available within weeks.
"I used to be in the clinic for many years. And after a family found out their child had been born with hearing loss no one was ever able to say to them: 'You know what? We have a treatment so that they can hear,'" Whitton says. "Now for the first time we are talking about medicines that actually enable the ear to hear. It's the beginning of a new era, honestly."
The FDA's decision was based on the results from the treatment of 20 patients born with a defective version of a gene known as OTOF, which is necessary to transmit sound from the ears to the brain.
How the treatment works
Doctor infused billions of adeno-associated viruses into the patients' ears by making a small incision behind the ear to open a small hole in the skull. The viruses carried a healthy version of the OTOF gene that had been split in half to fit inside the virus. The gene provides instructions to make the otoferlin protein, which is necessary for hair cells in the inner ear to transmit sound to the brain.
Most of the patients began to hear for the first time within weeks, with the quality of their hearing improving over the following months, according to Regeneron. The amount of hearing patients gained varied, but 80% achieved at least some significant hearing restoration and 42% ended up with normal hearing, which included the ability to hear whispers, Regeneron says. The hearing ability has lasted at least two years so far.
"These are incredible results for somebody like me who been in this field for a couple of decades. It's something I hadn't imagined only a few years ago could be possible," Whitton says. "What we've seen has been quite remarkable."
The treatment can only help patients with the very rare form of deafness that Smith was born with, which only affects about 50 children each year in the U.S. But similar gene therapies are showing promise for other forms of genetic deafness. And researchers hope someday gene therapy may help with common types of hearing loss, like from aging and loud noise.
But some worry the focus on reversing deafness could further stigmatize deaf people.
"These kind of genetic therapies seem to reinforce this idea of deafness being a problem in need of eradication, and that the only solution for disabled people to fully assimilate into society is through a medical intervention," says Jaipreet Virdi, who studies the history of medicine, technology and deafness at the University of Victoria in Canada and is herself deaf. "We're saying: 'Oh, deafness is a problem and we must fix that.'"
For her part, Sierra Smith is just thrilled she had this option for her son, even though the treatment has not yet fully restored his hearing.
"It's incredible. Now he can hear me tell him how much I love him," she says. "And he knows has a name now. And he's discovering all these different sounds," Smith says. "It's so mind-blowing. I feel like I'm so blessed and I'm the luckiest mom on earth."
